Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis

Scandinavian Journal of Immunology

Volumn 71, Issue 1, 2009, Pages 38-44

  Liu, H ^a   Li, W ^a   Gu, W ^a   Kong, Y ^a   Yang, N ^a   Chen, L ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CARVEDILOL; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PROTECTION; HEART RATE; IMMUNOMODULATION; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 72349090953     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02347.x     Document Type: Article

References (32)

1. Kodama M, Hanawa H, Saeki M et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994 75 : 278 284.
2. Kodama M, Matsumoto Y, Fujiwara M. In vivo lymphocyte-mediated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis. Circulation 1992 85 : 1918 1926.
3. Hanawa H, Abe S, Hayashi M et al. Time course of gene expression in rat experimental autoimmune myocarditis. Clin Sci (Lond) 2002 103 : 623 632.
4. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002 91 : 988 998.
5. Okura Y, Yamamoto T, Goto S et al. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 1997 29 : 491 502.
6. Liu H, Hanawa H, Yoshida T et al. Effect of hydrodynamics-based gene delivery of plasmid DNA encoding interleukin-1 receptor antagonist-Ig for treatment of rat autoimmune myocarditis: possible mechanism for lymphocytes and non-cardiac cells. Circulation 2005 111 : 1593 1600.
7. Watanabe K, Nakazawa M, Fuse K et al. Protection against autoimmune myocarditis by gene transfer of interleukin-10 by electroporation. Circulation 2001 104 : 1098 1100.
8. Panina-Bordignon P, Mazzeo D, Lucia PD et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997 100 : 1513 1519.
9. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996 97 : 713 719.
10. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997 54 : 161 185.
11. Yue TL, Cheng HY, Lysko PG et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992 263 : 92 8.
12. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. USA carvedilol heart failure study group. N Engl J Med 1996 334 : 1349 1355.
13. Nishio R, Shioi T, Sasayama S, Matsumori A. Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol 2003 41 : 340 345.
14. Kurum T, Tatli E, Yuksel M. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Tex Heart Inst J 2007 34 : 52 9.
15. Yang E, Wang S, Kratz J, Cyronak MJ. Stereoselective analysis of carvedilol in human plasma using HPLC/MS/MS after chiral derivatization. J Pharm Biomed Anal 2004 36 : 609 615.
16. Borger P, Hoekstra Y, Esselink MT et al. Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Am J Respir Cell Mol Biol 1998 19 : 400 407.
17. Malfait AM, Malik AS, Marinova-Mutafchieva L, Butler DM, Maini RN, Feldmann M. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J Immunol 1999 162 : 6278 6283.
18. Nishii M, Inomata T, Niwano H et al. Beta2-Adrenergic agonists suppress rat autoimmune myocarditis: potential role of beta2-adrenergic stimulants as new therapeutic agents for myocarditis. Circulation 2006 114 : 936 944.
19. Yoshida T, Hanawa H, Toba K et al. Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res 2005 68 : 278 288.
20. Baldari C, Murray JA, Ghiara P, Cesareni G, Galeotti CL. A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in Saccharomyces cerevisiae. EMBO J 1987 6 : 229 234.
21. McIntyre KW, Stepan GJ, Kolinsky KD et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991 173 : 931 939.
22. Gabay C, Gigley J, Sipe J, Arend WP, Fantuzzi G. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur J Immunol 2001 31 : 490 499.
23. Suzuki K, Murtuza B, Smolenski RT et al. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 2001 104 : I308 I313.
24. Yang GY, Zhao YJ, Davidson BL, Betz AL. Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 1997 751 : 181 188.
25. Yang S, Li W, Liu W et al. IL-10 gene modified dendritic cells induced antigen-specific tolerance in experimental autoimmune myocarditis. Clin Immunol 2006 121 : 63 73. (Pubitemid 44380417)
26. Chang H, Hanawa H, Yoshida T et al. Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer. Circ J 2008 72 : 813 819.
27. Gilbert EM, Abraham WT, Olsen S et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996 94 : 2817 2825.
28. Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice. Circulation 1991 83 : 2021 2028.
29. Schwarz ER, Kersting PH, Reffelmann T et al. Cardioprotection by Carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart. J Cardiovasc Pharmacol Ther 2003 8 : 207 215.
30. Feuerstein R, Yue TL. A potent antioxidant, SB209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994 48 : 385 391.
31. Burnett JC Jr., Opgenorth TJ, Granger JP. The renal action of atrial natriuretic peptide during control of glomerular filtration. Kidney Int 1986 30 : 16 9.
32. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994 90 : 195 203.